Fund

China Reform Fund

国新基金

The China Reform Fund is a state-backed venture capital vehicle under China Reform Holdings (中国国新), a central state-owned capital operation platform. It has surfaced in elsewhere's corpus mainly as a lead investor in hard-tech and healthcare deals: it led the Series A+ round for CereMediTech (中科睿医), a neurology diagnostic startup, in late 2024 , and more recently led Baiyao Technology's round in mid-2026, backing the latter's AI-driven "virtual cell" platform . The fund typically invests at the Series A stage and co-invests alongside established VC firms such as BlueRun Ventures and Yunqi Capital. Elsewhere's corpus does not cover its founding date, fund size, or full mandate beyond these deal footprints.

AI-generated — may contain errors, please verify.

China Reform FundFund
国新基金
渲染中…
Mentioned in 4 articles

Coverage